38 results about "FOXO1" patented technology

The invention relates to the technical field of gene polymorphism detection, in particular to a detection method of yak FOXO1 gene single nucleotide polymorphism and a kit thereof. The detection method comprises the following steps: 1) preparing a yak FOXO1 gene amplification product; 2) synthesizing a high and low temperature interior label; 3) preparing an HRM-PCR (High Resolution Melt-Polymerase Chain Reaction) amplification product; 4) collecting a fluorescence signal. Compared with an HRM method used for detecting polymorphic sites in the prior art, a gene probe designed by the detection method is more accurate and flexible in positioning, is accurate in parting, does not need PCR post-processing, has high working efficiency and good repeatability and is low in sample quality and quantity requirements, especially, the concentration requirement of a DNA template can be lowered to 0.1ng / mu L, and time and labor are saved when a sample size is large. Meanwhile, the detection kit has the advantages of high sensitiveness, high detection speed and good stability.

The invention relates to a benzimidazole derivative 2-m-phenylaminobenzimidazolyl-1H-pyrazolyl-3-formamide of which the structural formula is disclosed in the specification. The benzimidazole derivative can promote growth of microzyme, enhance the metabolic activity of the microzyme, obviously lower the plasma triglyceride, total cholesterol and high density lipoprotein of a C57 BL / 6J mouse which is fed by high-fat feed for a long time, lower the contractive pressure and diastolic pressure of the model mouse, lower the fasting blood-glucose of the model mouse, improve the sugar tolerance of the mouse, influence the expression of SIRT1 and related genes (FOXO1, P53, PPARgamma and PGC-1alpha), and obviously improve the metabolism of glucose and fat; and therefore, the benzimidazole derivative can be used for preparing medicines for preventing and treating diabetes and complications thereof.

The present invention relates to uses of glycerokinase as a glucose metabolism disorder treatment target. According to the present invention, the results show that glycerokinase can catalyze glycerol to generate 3-phosphoglycerol so as to participate in gluconeogenesis, can regulate the expressions of gluconeogenesis enzyme glucose-6-phosphatase (G6pase) and phosphoenolpyruvate carboxykinase (PEPCK) through an AKT-FOXO1 signaling pathway so as to regulate gluconeogenesis, and can provide important effects in the maintaining of the blood glucose homeostasis, such that the glycerokinase and the regulator thereof are the new target for blood glucose regulation and diabetes treatment.

The present invention provides a molecular marker of a rhabdomyosarcoma fusion gene-related circular RNA and an application thereof. The molecular marker of the rhabdomyosarcoma PAX3-FOXO1 fusion gene-related circular RNA is F-circP3F, and the nuclear marker of the molecular marker The nucleotide sequence is shown in SEQ ID No.1. The F-circP3F provided by the present invention has high sensitivity and specificity for alveolar rhabdomyosarcoma, and can be used as a novel molecular marker for the detection of rhabdomyosarcoma. By optimizing the primers and RT-PCR reaction system, this method can successfully amplify F-circP3F in the case of low RNA content in alveolar rhabdomyosarcoma cells and tissues, with strong sensitivity and specificity; F-circP3F can not only be applied It can be used in the diagnosis, classification and prognosis evaluation of rhabdomyosarcoma, and may provide a new way for the study of epigenetic regulation and molecular diagnosis and treatment strategies of rhabdomyosarcoma.

The invention discloses a reagent used for detecting forkhead transcription factor O1 (FOXO1) gene mutation, a polymerase chain reaction (PCR) detection method and an application, belonging to the technical field of basic biological research and biological detection. The detection reagent comprises primers, peptide nucleic acid (PNA) fluorescent probes and wild type complementary PNA sequences, wherein the forward primers are shown in SEQ ID NO.1 and NO.3 in a sequence table; the reverse primers are shown in SEQ ID NO.2 and NO.4 in the sequence table; the PNA fluorescent probes are shown in SEQ ID NO.5 and NO.6 in the sequence table; and the wild type complementary PNA sequences are shown in SEQ ID NO.7 and NO.8 in the sequence table. The reagent can rapidly discover mutation of the FOXO1 gene in a Wnt signal pathway from the transcriptional level, has the obvious advantages of strong specificity, high sensitivity, and the like and provides a tool for anti-cancer drug screening, new targeted drug discussion and basic scientific research.

The invention discloses cattle FoxO1 gene mononucleotide polymorphism and a detection method thereof. The gene mononucleotide polymorphism comprises that: with a Qinchuan cattle whole genome DNA comprising the FoxO1 gene as a template, and with a primer pair P as primers, the Qinchuan cattle FoxO1 gene is subjected to PCR amplification; a restriction endonuclease HhaI is used for digesting the PCR amplification product, and the digested segment is subjected to agarose gel electrophoresis; and according to the electrophoresis result, base polymorphism on the 178132 site of the Qinchuan cattle FoxO1 gene is identified. The FoxO1 gene is important for animal muscle fat traits and growth traits. With the method, the molecular genetic marker closely related to Qinchuan cattle growth traits is screened and detected on a DNA level. The method is used in Qinchuan cattle assisted selection and molecular breeding, and assists in accelerating Qinchuan cattle breeding speed.

The present invention relates to a composition for fat formation inhibition and body fat reduction, containing hydrangenol as an active ingredient. A composition of the present invention reduces fat accumulation in fat cells, reduces the phosphorylation of a mammalian target of rapamycin (mTOR), and increases the phosphorylation of forkhead box O1 (FoxO1) so as to ultimately reduce the expressionof peroxisome proliferator-activated receptor gamma (PPAR gamma), thereby inhibiting the formation of triglycerides in adipocytes so as to exhibit anti-obesity effects. Therefore, a composition containing hydrangenol as an active ingredient, disclosed in the present specification, can be effectively used in the field of health functional foods or cosmetics for fat formation inhibition .

The invention relates to a benzothiazole derivative, a preparation method and an application thereof, wherein the benzothiazole derivative is 2-m-aniline benzothiazole-1H-pyrazole-3-formamide, and the structural formula of the benzothiazole derivative is represented by FORMULA. The benzothiazole derivative disclosed by the invention can accelerate the growth of saccharomycetes, strengthen the metabolic activity of the saccharomycetes, obviously reduce the plasma triglyceride, the total cholesterol and the high-density lipoprotein of C57 BL / 6J mice fed with high-fat feedstuff, reduce the systolic pressure and the diastolic pressure of model mice, reduce the fasting blood glucose of the model mice, improve the sugar tolerance of the mice, affect the expression of SIRT1 and relevant genes (FOXO1, P53, PPAB gamma and PGC-1 alpha), and obviously improve the sugar and fat metabolism of diabetic model mice. Therefore, the benzothiazole derivative can be applied to preparing medicines for preventing and treating diabetes mellitus and complications of the diabetes mellitus.

The present invention relates to a method of preparing vascular endothelial cells by transforming (transdifferentiating) adult fibroblasts and a composition, which includes vascular endothelial cells prepared according to the method, for preventing and treating ischemic diseases, the method including a step of transducing adult fibroblasts with a gene. In particular, the present invention confirms that five factors, Foxo1, Er71, Klf2, Tal1, and Lmo2, induce transdifferentiation of adult fibroblasts into induced vascular endothelial cells. Furthermore, the present invention confirms that three factors, Er71, Klf2, and Tal1 induce transdifferentiation of human adult fibroblasts into induced vascular endothelial cells. The resultant induced endothelial cells enable lower limb salvaging by angiogenesis in lower limb ischemic animal models, showing that the induced endothelial cells can be effectively used for prevention or treatment of ischemic diseases.